Xgeva vs Prolia. How do they compare?
Xgeva Vs. Prolia. How do they compare?
Xgeva and Prolia are both brand names for the generic drug denosumab. Both are injectable preparations, both are made by Amgen, and both have similar side effects, although Prolia does carry a black box warning for severe, life-threatening, hypocalcemia in advanced kidney disease, particularly in people with a metabolic condition called chronic kidney disease-mineral bone disorder (CKD-MBD). But there are also differences in their indications, the way they are given, and their dosage.
People who are receiving Prolia should not receive Xgeva and the converse is also true.
Both had interchangeable biosimilars approved on 5 March 2024. A interchangeable biosimilar is a biological product that can be substituted at the pharmacy for the reference biologic because there are no clinically meaningful differences in terms of safety, purity, and potency.
- Wyost is an interchangeable biosimilar for Xgeva.
- Jubbonti is an interchangeable biosimilar for Prolia.
Xgeva Vs. Prolia: What are the differences in their indications?
Xgeva may be used to:
- Prevent bone fractures and other skeletal conditions in people with multiple myeloma and other types of cancer that have spread to the bone
- Treat giant cell bone tumor in adults and teenagers whose bone structure is fully mature
- Treat high calcium levels caused by cancer that hasn’t responded to bisphosphonates.
Prolia may be used to:
- Treat osteoporosis in postmenopausal women at high risk of fracture
- Increase bone mass in men with osteoporosis at high risk for fracture
- Treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture
- Increase bone mass in men receiving androgen deprivation therapy at high risk for fracture
- Increase bone mass in women receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture.
Related questions
- What's the difference between Prolia and Reclast?
- Does Prolia weaken your immune system?
- How do you give a Prolia injection?
Xgeva Vs. Prolia: What are the differences in the way they are given?
Xgeva is given by subcutaneous injection (under the skin) and people can be taught how to self administer it. Prolia should be administered by a health care professional, even though it is still given subcutaneously.
Xgeva Vs. Prolia: What are the differences in their dosage?
Xgeva is given as a 120mg injection once every four weeks, with additional 120mg doses given on days 8 and 15 of the first month of therapy. Oral calcium and vitamin D should be given as necessary to treat or prevent low calcium levels (hypocalcemia).
Prolia is given as a single 60mg injection once every six months. All patients should receive 1000mg of calcium orally daily and at least 400IU vitamin D orally daily.
References
- Targeted Therapies for Osteoporosis and Bone Protection: Prolia and Xgeva. BreastCancer.org https://www.breastcancer.org/tips/bone_health/keep_bones_strong/targeted#:~:text=The%20targeted%20therapy%20Prolia%20(chemical,benefits%20from%20other%20osteoporosis%20treatments.
- Denosumab (Rx) Medscape https://reference.medscape.com/drug/xgeva-prolia-denosumab-999566
- Xgeva (denosumab) [Package Insert] 02/2020 Amgen Inc https://www.drugs.com/pro/xgeva.html
- Prolia (denosumaqb) [Package Insert] 01/2024. Amgen Inc https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Prolia/prolia_pi.pdf
Read next
Does Prolia cause weight gain?
Prolia (denosumab) has not been associated with weight gain in clinical studies. Prolia can cause peripheral edema (fluid retention) or swelling, and this may lead to weight gain in some people. Continue reading
Does Prolia increase bone density?
Prolia (denosumab) does increase bone density. Prolia works by targeting a molecule called RANKL that osteoclasts need to work. By stopping RANKL from binding to its receptor Prolia reduces bone breakdown, bone loss, bone pain, and other bone complications. BMD was increased by 8.8% at the lumbar spine, 6.4% at the total hip, and 5.2% at the femoral neck in trials that measured BMD after three years of treatment with Prolia. Continue reading
Evenity vs Prolia: Which is right for you?
Evenity (romosozumab-aqqg) and Prolia (denosumab) are two injectable medications that help lower the risk of bone fracture. When deciding which treatment option is best for you, it is important to consider factors such as who these medications are approved for, dosing, and side effects. Continue reading
Related medical questions
- Can you drink alcohol while taking Prolia?
- How many years should you take Prolia?
- How long will the side effects of Prolia last?
- What biosimilars have been approved in the United States?
- What medications are available to treat osteoporosis?
- Insights from a Pharmacist about Osteoporosis Treatments
- How can I prevent osteoporosis?
Drug information
Related support groups
- Prolia (45 questions, 222 members)
- Xgeva (9 questions, 33 members)
- Osteoporosis (69 questions, 293 members)
- Hypercalcemia of Malignancy (6 questions, 9 members)
- Osteolytic Bone Lesions of Multiple Myeloma (5 questions, 8 members)
- Osteolytic Bone Metastases of Solid Tumors (5 questions, 11 members)
- Giant Cell Tumor of Bone (2 questions, 4 members)